Growth Metrics

Merck (MRK) Net Income towards Common Stockholders Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 76.51%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 131.31%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 109.43%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -51.68%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -13.81%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 27.11%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -146.62%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 5.72%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -51.68%
Dec 31, 2024 296.61%
Jun 30, 2024 154.32%
Mar 31, 2024 121.78%
Dec 31, 2023 -63.17%
Sep 30, 2023 97.46%
Jun 30, 2023 -122.28%
Mar 31, 2023 -4.26%
Dec 31, 2021 -26.72%
Jun 30, 2021 -42.16%
Mar 31, 2021 -16.14%
Dec 31, 2020 35.79%
Sep 30, 2020 141.58%
Jun 30, 2020 -30.29%
Mar 31, 2020 27.42%
Dec 31, 2019 -45.50%
Sep 30, 2019 -4.48%
Jun 30, 2019 29.80%
Mar 31, 2019 36.31%
Dec 31, 2018 21.88%
Sep 30, 2018 2.26%
Jun 30, 2018 35.62%
Mar 31, 2018 -8.21%
Dec 31, 2017 -28.90%
Sep 30, 2017 -27.25%
Jun 30, 2017 -1.36%
Mar 31, 2017 -3.49%
Dec 31, 2016 -39.59%
Sep 30, 2016 23.91%
Jun 30, 2016 8.94%
Mar 31, 2016 -11.24%
Dec 31, 2015 38.51%
Sep 30, 2015 1.27%
Jun 30, 2015 -27.69%
Mar 31, 2015 -18.46%
Dec 31, 2014 117.56%
Sep 30, 2014 -21.25%
Jun 30, 2014 -0.34%
Mar 31, 2014 48.14%
Dec 31, 2013 30.05%
Sep 30, 2013 36.65%
Jun 30, 2013 36.89%
Mar 31, 2013 40.40%
Dec 31, 2012 -28.78%
Sep 30, 2012 54.61%
Jun 30, 2012 42.20%
Mar 31, 2012 30.08%